Market Overview

Ancora Heart Announces Key Activities for Transcatheter Cardiovascular Therapeutics 2018

Share:

Interim Data Will Be Presented from Safety Study of First-of-Its-Kind
Heart Failure Therapy

Ancora Heart, Inc., a company developing a novel therapy to address
heart failure, today announced the company's key activities at the 30th
Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific
symposium of the Cardiovascular Research Foundation in San Diego.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180910005302/en/

Interim data will be presented from the recently expanded U.S. early
feasibility study evaluating the safety of the investigational AccuCinch® Ventricular
Repair System designed for the treatment of heart failure and functional
mitral regurgitation (FMR).

Ancora Heart's primary TCT conference activities include:

Saturday, September 22

  • Didactic Session: Interventional Heart Failure and Hemodynamic
    Support, Part 1, Percutaneous Ventricular Reshaping of the LV for
    Chronic Heart Failure: Ancora
  • Presented by Daniel Burkhoff, M.D. at 11:44 am in Room 6D, Upper
    Level

Sunday, September 23

  • Didactic Session: Transcatheter Mitral Valve Therapies, Part 1 -
    Mitral Valve Repair, AccuCinch Basal Ventriculoplasty for
    Functional MR and Heart Failure: Device, Procedure, and Updated
    Outcomes
  • Presented by Mark Reisman, M.D. at 5:05 pm in Room 1, Upper Level

Ancora Heart's AccuCinch therapy has the potential to treat heart
failure and FMR patients in whom the disease has progressed beyond the
ability for medications and pacemakers to manage symptoms or for whom
the risks of open-heart surgery are too high. Unlike current
technologies that replicate surgical procedures to replace or repair an
otherwise-normal mitral valve, AccuCinch is designed to repair the left
ventricle directly to address the fundamental cause of heart failure.

About Ancora Heart

Ancora Heart, Inc., based in Santa Clara, Calif., is dedicated to
helping people with heart failure feel better and live longer. Ancora
Heart has developed the AccuCinch System, an investigational therapy
designed to repair the enlarged left ventricle targeting the underlying
cause of heart failure. The AccuCinch heart failure treatment was
created to benefit the millions of patients who otherwise have no
minimally invasive option available to them. For more information visit www.ancoraheart.com.

View Comments and Join the Discussion!
 
Fastest news service for the smartest traders
$147 Free 14 day Trial